<DOC>
	<DOCNO>NCT01574716</DOCNO>
	<brief_summary>This study do see MORAb-004 increase effectiveness chemotherapy gemcitabine docetaxel people metastatic Soft Tissue Sarcoma .</brief_summary>
	<brief_title>Sarcoma Study MORAb-004 Utilization : Research Clinical Evaluation . ( SOURCE )</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Be least 18 year age Be surgically sterile consent use medically acceptable method contraception throughout study period Have histologically confirm diagnosis mSTS define 4 specify study subgrouped Have treat metastatic set 0 2 prior systemic regimen mSTS ( Systemic treatment regimen give neoadjuvant set maintenance therapy consider regimen metastatic setting purpose protocol . Prior anthracyclinebased regimen allowable require . Subjects extraskeletal small round blue cell sarcoma , include rhabdomyosarcoma , must exhaust intolerant standard first line anthracyclinebased chemotherapy . ) Have measurable disease , define RECIST v 1.1 ass within 2 week study entry radiologically document disease progression great equal 10 % increase sum long diameter target lesion present within 6 month prior randomization Have tumor tissue available TEM1 biomarker study Be willing able provide write informed consent Have receive 2 prior systemic treatment regimen mSTS Have receive either gemcitabine docetaxel previous treatment mSTS ( regardless line treatment ) Have diagnosis primary bone sarcoma histological type . Have history clinically significant heart disease , clinically significant arrhythmia ECG within past 6 month Have history allergic reaction prior monoclonal antibody biologic agent Have receive previous treatment MORAb004 ( antiTEM1 ) Have medical condition high risk bleeding ( e.g. , know bleed disorder , coagulopathy , tumor involve major vessel ) recent ( within past 6 month ) history significant bleeding event Have undergone major surgical procedure open biopsy , significant traumatic injury within 30 day prior first date study treatment , major surgical procedure anticipate study Have serious nonhealing wound , ulcer ( include gastrointestinal ) , bone fracture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>